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MOLECULAR PAIN

RESEARCH

Open Access

Analgesic effect of a mixed T-type channel
inhibitor/CB2 receptor agonist
Vinicius M Gadotti1, Haitao You1, Ravil R Petrov2, N Daniel Berger1, Philippe Diaz2 and Gerald W Zamponi1*

Abstract
Background: Cannabinoid receptors and T-type calcium channels are potential targets for treating pain. Here we
report on the design, synthesis and analgesic properties of a new mixed cannabinoid/T-type channel ligand,
NMP-181.
Results: NMP-181 action on CB1 and CB2 receptors was characterized in radioligand binding and in vitro GTPγ[35S]
functional assays, and block of transiently expressed human Cav3.2 T-type channels by NMP-181 was analyzed by
patch clamp. The analgesic effects and in vivo mechanism of action of NMP-181 delivered spinally or systemically
were analyzed in formalin and CFA mouse models of pain. NMP-181 inhibited peak CaV3.2 currents with IC50 values
in the low micromolar range and acted as a CB2 agonist. Inactivated state dependence further augmented the
inhibitory action of NMP-181. NMP-181 produced a dose-dependent antinociceptive effect when administered
either spinally or systemically in both phases of the formalin test. Both i.t. and i.p. treatment of mice with NMP-181
reversed the mechanical hyperalgesia induced by CFA injection. NMP-181 showed no antinocieptive effect in CaV3.2
null mice. The antinociceptive effect of intrathecally delivered NMP-181 in the formalin test was reversed by i.t.
treatment of mice with AM-630 (CB2 antagonist). In contrast, the NMP-181-induced antinociception was not
affected by treatment of mice with AM-281 (CB1 antagonist).
Conclusions: Our work shows that both T-type channels as well as CB2 receptors play a role in the antinociceptive
action of NMP-181, and also provides a novel avenue for suppressing chronic pain through novel mixed
T-type/cannabinoid receptor ligands.
Keywords: T-type Channels, Cannabinoid Receptors, Pain, Patch-Clamp, Mice

Background
In recent decades, our knowledge of the mechanisms
underlying pain sensation has improved substantially;
however, despite the increased understanding of the
neurobiology of pain and the discovery of new painmediating molecules, only few novel classes of analgesic
compounds have entered the clinic. Therefore, the identification of new pharmacophores for analgesics is of
critical importance. Although the drug discovery sector
frequently focuses on the design of highly specific
channel and receptor modulators, the use of compounds
that interact with more than one molecular target may
provide opportunities for synergistic actions to increase
analgesic efficacy [1].
* Correspondence: zamponi@ucalgary.ca
1
Department of Physiology and Pharmacology, Hotchkiss Brain Institute,
University of Calgary, Calgary, Canada
Full list of author information is available at the end of the article

Low-voltage activated (LVA) T-type calcium channels
are essential contributors to signalling in electrically
excitable cells [2-5] and are well recognized as important
regulators of pain transmission [6-8]. T-type channels
are highly expressed in primary afferent pain fibers with
the highest expression levels in medium sized dorsal
root ganglion (DRG) neurons [9]. Inhibition of T-type
channels by intrathecal [7,10] or systemic [11] delivery
of synthetic compounds, or through selective subunit
knockdown via antisense oligonucleotides [7,12-14]
has been shown to produce potent analgesic effects in
rodents. Exactly how T-type channels contribute to pain
processing is unclear, but may involve a regulation of
the excitability of the primary afferent fiber and/or a
contribution to neurotransmission at dorsal horn synapses [6,15,16]. Cannabinoid receptors on the other hand
are G‑protein-coupled receptors [17] that are activated
by cannabinoid ligands such as the phytocannabinoid
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Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.

Gadotti et al. Molecular Pain 2013, 9:32
http://www.molecularpain.com/content/9/1/32

Δ9-tetrahydrocannabinol (Δ9-THC) and endogenous
cannabinoids such as anandamide and 2-arachidonyl
glycerol (2-AG) [18]. These ligands bind to the two
members of the CB receptor family - CB1 and CB2 [19,20].
Cannanbinoids have shown efficacy in relieving pain in
randomized-controlled trials often without serious adverse
effects [21] and also they show therapeutic action in the
treatment of pain associated with diseases such as multiple
sclerosis [22,23]. Recent reports suggest that CB1 agonism
can play a role in the analgesic effects of selective CB2
agonists in the rat CFA model [24]. A very low occupancy
of CB1 receptors (<10%) by an agonist with a relatively low
intrinsic efficacy can induce neurochemical and behavioral
effects resulting in antinociception [25]. Remarkably,
many endocannabinoids (such as anandamide) [26-28]
and phytocannabinoids (Δ9-tetrahydrocannabinol and
cannabidiol) [29,30] can also block T-type calcium
channels, resulting in a more pronounced analgesia. This
then suggests that such mixed cannabinoid receptor
agonists with low intrinsic efficacy and T-type channel
antagonists may produce synergistic actions with fewer
side effects that may be exploited for analgesia.
In this study, we synthesized and pharmacologically
characterized a novel compound NMP-181 (Figure 1) that
exhibits a low intrinsic CB2 efficacy and potent T-type
channel blocking activity. This compound was characterized in cell models, and was evaluated in various in vivo
models for analgesic properties. Our data show that
NMP-181 interferes with pain transmission through a
mechanism related to CB2 receptor activation and CaV3.2
channel inhibition but without nonspecific sedative actions, indicated by the inability of the active dose used
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in our pain model to affect the locomotor activity of
mice on open-field test.

Results
In vitro characterization of putative tricyclic T-type
channel inhibitors

We previously reported on a novel series of tricyclic
compounds that were capable of interacting with both
cannabinoid receptors and T-type calcium channels
[31]. Based on our previous SAR data, we identified a core
pharmacophore and synthesized NMP-181(Figure 1) as a
possible dual CB2/T-type channel ligand. We first tested
the ability of NMP-181 to inhibit transiently expressed
T-type channels in tsA-201 cells. A concentration-response
curve revealed that the inhibitory effect of NMP-181 on
CaV3.2 occurred with an IC50 of 4.6 μM and a Hill coefficient of 2.1, indicating cooperativity between multiple
blocking modes (Figure 2A). Figure 2B illustrates the timecourse of the effect of NMP-181 on CaV3.2 peak current
amplitude, revealing a rapid onset of block and only partial
reversibility. To evaluate whether this compound was
able to block other CaV3 isoforms, 10 μM of NMP-181
was tested on transiently expressed human CaV3.1 and
CaV3.3 channels at a test potential of −20 mV. As seen in
Figure 2C,D, the degree of inhibition was similar for all
three CaV3 isoforms. Application of NMP-181 to CaV3.2
channels produced a mild but significant hyperpolarizing
in half-activation potential from −32.7 mV to −38.4 mV
(n = 5, P < 0.05) (Figure 2E). Many of T-type channel
blockers have state-dependent inhibitory effects, with
enhanced potency at depolarized holding potentials
[11,31,32]. To determine whether NMP-181 block is similarly state dependent, we recorded steady-state inactivation
curves before and after application of NMP-181. As shown
in Figure 2F, application of 10 μM of NMP-181 shifted the
half-inactivation potential of CaV3.2 channels towards
more hyperpolarized potentials from −56.0 mV to −64.1
mV (n = 4, P < 0.01). These data imply that at a typical
neuronal resting membrane potential additional T-type
channel inhibition can occur due to a drug induced reduction in channel availability. Altogether, our data indicate that
NMP-181 mediates T-type channel inhibition with affinities
in the low micromolar range and possibly lower at more
depolarized resting membrane potentials or as a result
of frequency-dependent inhibition.
Cannabinoid receptor affinity of NMP-181

Figure 1 Molecular Structure of NMP-181.

NMP-181 was also tested for its cannabinoid activities
using CB1 and CB2 binding assays. NMP-181 displaced
respectively 65.4% and 60.5% of [3H]CP55,490 in HEK293
cells expressing human CB2 receptors, and in rat brain homogenates expressing CB1 receptors at 10 μM. NMP-181
exhibited the best affinity for CB2 receptors with a Ki value
of 123 nM at human CB2 receptors and > 2 μM at rat CB1

Gadotti et al. Molecular Pain 2013, 9:32
http://www.molecularpain.com/content/9/1/32

Page 3 of 11

Figure 2 Pharmacological and biophysical properties of NMP-181 block of T-type calcium channels. (A) concentration dependence of
NMP-181 inhibition of the CaV3.2 peak current amplitude. The data were fitted with a Hill equation. The half-maximal inhibitory concentration
(IC50) from the fit was 4.6 μM and the Hill coefficient was 2.1. Numbers in parentheses reflect numbers of experiments for each concentration
point. (B) representative time course of the development of and recovery from NMP-181 (30 μM) inhibition. (C), NMP-181 (10 μM) did not show
selectivity on CaV3 channels, as illustrated in the histogram and (D) representative traces from NMP-181 inhibition on CaV3.1, 3.2 and 3.3 currents.
Statistical significance was determined by one-way ANOVA followed by a Dunnett’s test, when the data were compared to those from CaV3.2
group. (E) normalized current–voltage relations of CaV3.2 current before and after application of 10 μM NMP-181. The half-activation
potentials were −32.7 ± 2.0 mV and −38.4 ± 2.8 mV before and after application of NMP-181, respectively (inset, P < 0.05, paired t test).
(F) steady-state inactivation curve obtained from CaV3.2 channels before and after application of 10 μM NMP-181. The half-inactivation
potentials were −56.0 ± 2.8 mV and −64.1 ± 4.0 mV before and after the treatment with NMP-181, respectively (inset, P < 0.01, paired t test).
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Table 1 Radioligand competitive binding assays and GTPγ[35S] functional activity
GTPγ[35S] functional assays

Mean Ki
Ligand
NMP181

Human CB1

Human CB2

Rat CB1
(nM)

Human CB2
(nM)

EC50 (μM)

Emax (%)

EC50 (μM)

% activation average at 1 μM

2238 ± 515

123 ± 28

NA

ND

>1

24%

ND not done, NA not active at 1 μM.

receptors (Table 1). NMP-181 exhibited low intrinsic activity at human CB2 receptors since only 24% of activation
was detected at 1 μM in GTPγ[35S] functional assays. No
functional activity was detected at lower concentrations.
These data indicate that NMP-181 acts as a preferential
agonist of CB2 receptors over the CB1 subtype.

of mice 30 minutes before formalin injection resulted in a
significantly (one-way ANOVA) decreased pain response
time in both the first (Figure 3C) and second (Figure 3D)
phases (41±3% and 44±8% inhibition, respectively).
Importantly, neither spinal (via i.t.) nor systemic (via i.p.)
treatment with NMP-181 affected locomotor activity of
mice assessed via an open-field test (Figure 3E, F).

Effect of NMP-181 on formalin-induced nociception

Given the agonist activity on CB2 receptors and the
concomitant T-type channel antagonist activity, we
hypothesized that this compound may show efficacy in
models of inflammatory pain. NMP-181 was delivered by
the i.t. route and its effects on both the acute nociceptive
and the slower inflammatory pain phases of a formalin test
were evaluated [33]. Mice were treated i.t. with NMP-181
or control solution (PBS + DMSO 5%) 15 minutes prior to
behavioural assessment. One-way ANOVA revealed that i.t.
treatment of mice with NMP-181 (1–10 μg i.t.-1) significantly reduced pain response time in both first (Figure 3A)
and second (Figure 3B) phases (55±5% and 66±4% inhibition, respectively). Intraperitoneal (i.p.) treatment

Effect of NMP-181 on CFA-induced persistent
inflammatory nociception

To ascertain whether NMP-181 modulates pain transmission under chronic inflammatory conditions, we analysed
the nociceptive response of NMP-181 treated mice after
CFA injection. As shown in Figure 4A, B, mice injected with
CFA developed mechanical hyperalgesia 3 days after CFA
injection as indicated by a significant decrease of withdrawal
thresholds when compared to pre-CFA baseline levels of the
control group (P < 0.001). Two-way ANOVA revealed that
spinal treatment of mice with NMP-181 (10 μg i.t.-1) significantly attenuated the mechanical hyperalgesia induced by
CFA when compared with the CFA + PBS (control) group,

Figure 3 Effect of NMP-181 administered by either i.t. (A,C) or i.p. (B,D) routes on the first and second phases of formalin-induced
(A,B) pain and mice crossing in the open-field test (C,D). Each bar or individual point represents the mean responses from 6–8 animals and
the error bars indicate the S.E.M. Control values (indicated by “0”) are from animals injected with 5% of DMSO in PBS and the asterisks denote the
significance relative to the respective control group. **P<0.01; ***P<0.001. (one-way ANOVA followed by Tukey’s test).
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Figure 4 Effect of NMP-181 delivered via i.t. (A) or i.p. (B) on the mechanical hyperalgesia induced by intraplantar delivery of CFA.
Each circle represents the mean responses from 7–8 animals and the error bars indicate the S.E.M. Control values (indicated by black circles) are
from animals injected with 5% of DMSO in PBS and the asterisks denote the significance relative to the control group. *P<0.05; **P<0.01 and
###
P<0.001 when compared to PBS intraplantar group (two-way ANOVA followed by Tukey’s test).

at 20 minutes (P < 0.01) and 40 minutes (P < 0.05) after
NMP-181 treatment (Figure 4A). When mice were treated
with NMP-181 systemically (1 mg kg-1, i.p.), mechanical
hyperalgesia induced by CFA was significantly attenuated
at 30 minutes (P < 0.01) and 60 minutes (P < 0.05) after
treatment when compared with the CFA + PBS (control)
group (Figure 4B). These data indicate that NMP-181 is
a regulator of chronic inflammatory pain when delivered

either through i.t or i.p. routes. Altogether, these data
indicate that NMP-181 treatment specifically modulates
pain signalling and mediates analgesia when delivered
either spinally or systemically to mice.
Analysis of mechanism of action of NMP-181

To investigate if T-type calcium channels play a role in the
analgesic effect of NMP-181, we performed a formalin test

Figure 5 Effect of NMP-181 delivered via i.t. to CaV3.2 null mice on first (C) and second (D) phases of formalin induced pain. CaV3.2 null
mice exhibit decreased pain response time when compared to wild-type animal on first (A) and second (B) phases of formalin induced pain.
Each bar represents the mean responses from 6 animals and the error bars indicate the S.E.M. Control values (indicated by “C”) are from animals
injected with 5% of DMSO in PBS (one-way ANOVA followed by Tukey’s test).
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in CaV3.2 null mice that were treated either with vehicle or
with NMP-181 (10 μg i.t.-1) and as shown in Figure 5A, B,
CaV3.2 null mice exhibited a lower mean response time
when compared to wild-type mice, in agreement with
previous data from [34]. As indicated in Figure 5C, D
CaV3.2 null mice appear to be completely insensitive to
i.t. treatment with NMP-181 (10 μg i.t.-1) as revealed by
one-way ANOVA. At face value, these data suggest that
NMP-181 may predominantly inhibit pain signalling via
T-type channel inhibition.
Intrathecal treatment of mice with the CB2 antagonist AM-630 (1 μg/i.t.), in combination with NMP-181
(10 μg/i.t.), significantly attenuated the antinociceptive
action of NMP-181 (10 μg/i.t.) (Figure 6A, B) in both
phases of formalin-induced pain as revealed by two-way
ANOVA ([NMP-181 treatment F(1.65)=5.4, P <0.001 and
NMP-181 × AM-630 + NMP-181 interaction: F(1.75)=4.5,
P<0.001] for the first phase and [NMP-181 treatment F
(2.87)=5.4, P <0.001 and NMP-181 × AM-630 + NMP-181
interaction F(1.67)=5.4, P<0.05] for the second phase). As a
positive control, we used JZL-184 (3 μg/i.t., a dose which
in itself produced a 50% reduction in response time; data
not shown), an irreversible inhibitor for monoacylglycerol
lipase, which is the primary enzyme responsible for
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degrading the endocannabinoid 2-arachidonoylglycerol.
Although AM-630 is considered highly selective for CB2,
it is remotely possible that AM-630 could somehow have
affected NMP-181 block of T-type channels. However, the
fact that NMP-181 was still active in CaV3.2 KO mice
supports the idea that NMP-181 acts via more than one
target, and based on the AM-630 data, we thus conclude
that CB2 receptors also contribute to the analgesic effect
of NMP-181.
In contrast, intrathecal treatment of mice with the CB1
antagonist AM-281 (2 μg/i.t.), in combination with NMP181 (10 μg/i.t.), did not modify the antinociception caused
by NMP-181 (10 μg/i.t.) in the formalin test (Figure 6C, D),
excluding an involvement of the CB1 receptor in the
analgesic action of NMP-181. Importantly the dose of
AM-281 used was able to significantly reverse the analgesic action of URB-597 (10 μg/i.t., a dose that resulted
in a >50% reduction in response time, data not shown), an
inhibitor of the enzyme fatty acid amide hydrolase, which is
the primary degradatory enzyme for the endocannabinoid
anandamide. Collectively these data show that intrathecal
delivery of NMP-181 mediates its analgesic actions through
a combination of CaV3.2 channel inhibition and CB2
receptor stimulation.

Figure 6 Effect of i.t. treatment with selective CB2 (A, B) or CB1 (C, D) receptor antagonists on the antinociceptive action of NMP-181
on first (A, C) and second (B, D) phases of formalin-induced pain in mice. Each bar represents the mean responses from 6–8 animals and
the error bars indicate the S.E.M. Control values (indicated by “C”) are from animals injected with 5% of DMSO in PBS and the asterisks denote the
significance relative to the control group. *P<0.05; ***P<0.001 and #P<0.05; ###P<0.001 when compared to NMP-181 alone or positive controls
treated groups (two-way ANOVA followed by Tukey’s test).
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Discussion
After the identification of the CB1 [19] and CB2 [20]
receptors for delta-nine-tetrahydrocannabinol (Δ9-THC)
in mammals, various pharmaceutical strategies have
attempted to explore the potential therapeutic properties of
the cannabinoid system while minimizing its problematic
side effects [35,36]. A significant problem surrounding
the medical use of cannabis-related compounds is a concern regarding their CB1-mediated psychoactive effects and
abuse potential [37]. The interest in developing compounds
whose mechanism of action involves the CB2 receptors
without CB1 involvement, and thus without CB1-mediated
psychotropic side effects, still remains a goal in medical
therapeutics. For this reason, selective CB2 receptor
ligands appear as potentially viable compounds for pain
management. CB2 activation suppresses microglial cell
activation [38] and decreases neuroinflammation [39]
which are common underlying mechanisms that lead to
pathological pain [40] even though involvment of CB1
receptor cannot be excluded in these effects [24]. In
addtion, cannabinoid receptors may couple to other effectors such as N-type calcium channels that are critical for
the transmission of pain signals [41-43]. Interestingly,
either Δ9-THC and cannabidiol [30] or the endogenous
cannabinoid anandamide and its derivatives [26,28,44]
inhibit T-type channel activity, thus mediating neuronal
excitability via a receptor-independent mechanism. Given
that blockade of the T-type channel subtype CaV3.2 results
in antinociceptive, anti-hyperalgesic, and anti-allodynic
effects [11], the use of mixed CB2/T-type calcium channel
ligand may provide a potential strategy for the development
of more effective analgesics. Combining different mechanisms of action in a single drug could represent many
advantages. These may include a gain of potency and
duration of effects, a reduced number of prescribed drugs
for a given condition, and perhaps a reduction of sideeffects, as synergistic action on two targets may require
an overall lower dose. We were thus interested in identifying a CB2 (but not CB1) agonist with T-type channel
blocking ability. Here, we present a new compound of this
class, NMP-181, which mediates analgesia in vivo dosedependently and through a mechanism involving CB2
receptor activation and T-type calcium channel blockade.
Our results demonstrate that NMP-181 administered
spinally (via i.t.) or systemically (i.p.) inhibits biphasic
(neurogenic and inflammatory) pain induced by formalin
in mice. This effect was greater during the second inflammatory pain phase of the test, indicating that NMP-181
strongly modulates inflammatory pain. In the formalin
test, the neurogenic phase is elicited by direct activation of
nociceptive terminals; whereas a combination of peripheral and central mechanisms underlies the inflammatory
phase [33,45]. As chronic pain differs substantially from
acute pain in terms of its persistence and adaptive changes
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such as neuroplasticity in the nervous system, we also
assessed the action of NMP-181 in a persistent inflammatory pain model. Indeed, we demonstrated that NMP-181
delivered either spinally (via i.t.) or systemically (via i.p.)
inhibited mechanical hyperalgesia induced by CFA at doses
that did not seem to be directly associated with nonspecific
sedative actions, indicated by the inability of these
doses to affect the locomotor activity of mice in an
open-field test. The CFA model of persistent pain produces central sensitization in response to the release of
several pro-inflammatory mediators, which cumulatively
increase the sensitivity of peripheral and central sensory
pathways [46].
Our data reveal that the CB2 receptor, but not the CB1
receptor, is likely involved in the analgesic effects of NMP181, as the effects of NMP-181 were partially reversed by
AM-630, but not AM-281. At the same time, it is interesting to note that NMP-181 was completely ineffective in in
CaV3.2 null mice (Figure 5C, D), although the null mice
themselves showed only a partial reduction in nocifensive
behavior that in itself was smaller than the effect of
NMP-181 in wild type animals (compare Figure 5A, B
with Figure 3A, B). It is possible that CaV3.2 null mice
develop compensatory mechanisms that are insensitive
to NMP-181. It is also possible that the NMP-181 mediated activation of CB2 receptors might trigger its analgesic
effects in part via second messenger mediated inhibition of
CaV3.2 channel activity. This then might explain why null
mice are completely insensitive to NMP-181 even though
they presumably still express CB2 receptors. Finally, we
note that the effects of NMP-181 on CaV3.2 channels
appeared to be state dependent, resulting in analgesia.
Altogether, our data support a mechanism of which
dual action of NMP-181 on CB2 receptors and CaV3.2
calcium channels.
With regard to CaV3.2, NMP-181 also mediated a
hyperpolarzing shift in half inactivation potential that
would be expected to produce additional inhibitory effects due to reduced channel availability at normal
resting potentials. Such a feature is often associated
with frequency dependent inhibition [6,32] which is a
desirable feature in a drug designed to inhibit cellular
excitability, such as in epilepsy [47], cardiac arrhythmias [48] and pain [30,49].

Conclusions
Altogether, this study shows that NMP-181 exerts a rapid
onset and pronounced antinociceptive effect in mice when
administered spinally and systemically, at doses that do not
interfere with locomotor activity. The NMP-181 scaffold
may thus serve as a new pharmacophore for the development of new, more potent and longer-lasting mixed
CB2/T-type channel ligands.
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Methods
Chemical synthesis

NMP-181 was synthesized at the Core Laboratory for
Neuromolecular Production. Full analytical data and
detailed synthesis protocol are available in the supporting
information (Additional file 1). NMP-181 was prepared in a
four-step sequence starting with carbazole which was first
alkylated and then formylated. Oxidation of the resulting
aldhehyde followed by amidification afforded NMP-181.
NMP-181 base was used for in vitro studies and NMP-181
hydrochloride was used for the in vivo studies.
cDNA constructs

The cDNAs encoding human CaV3.2 and CaV3.3 were
generously provided by Drs. Arnaud Monteil (CNRS
Montpellier) and Terrance Snutch (University of British
Columbia), respectively. The isolation of human CaV3.1
cDNA in our laboratory was described previously [27].
The cDNA encoding the human CB1 receptor was isolated
from a human brain stem cDNA library [50]. Sequencing
confirmed that it was identical to GenBank Accession
X54937. The coding sequence of the human CB1 receptor
was subcloned as a HindIII-XbaI 1.5 kb DNA fragment in
the expression vector pCDNA3 and in a bicistronic expression vector. The human CB2 receptor was cloned by PCR
using oligonucleotides based on the sequence published by
Munro and colleagues [20] with human genomic DNA as
template. Sequencing of the resulting clones identified a
fragment of 1.1 kb encoding the human cannabinoid 2
receptor, identical to GenBank Accession X74328. The coding sequence of the human CB2 receptor was inserted into
bicistronic expression plasmids as a BamHI-NheI fragment
and was subcloned as a BamHI-NheI DNA fragment in a
BamHI-XbaI expression vector pCDNA3 (Invitrogen). The
sequences of human CB2, used in the binding studies are
the NCBI Reference Sequence.
Cell culture and transfection

HEK293 cells and CHO cells were used in radioligand
binding assays while tsA-201 cells were used in electrophysiological studies. Human CB2 (used in the binding
studies) was cloned into pcDNA5.0FRT and cell lines were
made using the FlpIn system from Invitrogen. tsA-201 cell
culture and transient transfection of calcium channels
were described previously [51]. In brief, CaV3.1, 3.2 and
3.3 α1 subunits were transfected individually with yellow
fluorescent protein in tsA-201 cells using the calcium
phosphate method.
In vitro receptor radioligand CB1 and CB2 binding studies

CB1 and CB2 radioligand binding data were obtained using
National Institute of Mental Health (NIMH) Psychoactive
Drug Screening Program (PDSP) resources as described earlier [31,52-54]. Compounds were screened
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in a competitive binding experiment using, respectively,
membrane fractions prepared from rat brain homogenate
expressing CB1 receptor and HEK293 cells expressing the
human CB2 receptor. The competition binding experiment for CB1 and CB2 was performed in 96 well plates
containing Standard Binding Buffer (50 mM Tris HCl, 1
mM EDTA, 3 mM MgCl2, 5 mg ml-1 fatty acid-free BSA,
pH 7.4). The radioligand was [3H]CP55940, and the reference compound was CP55940. A solution of the compound to be tested was prepared as a 1 mg ml-1 stock
in DMSO and then diluted in Standard Binding Buffer
by serial dilution. Radioligand was diluted to five times
the assay concentration in Standard Binding Buffer.
Aliquots (50 μl) of radioligand were dispensed into the
wells of a 96-well plate containing 100 μl of Standard
Binding Buffer. Then, duplicate 50-μl aliquots of the test
and reference compound dilutions were added. Finally,
crude membrane fractions of cells were resuspended in
3 ml of chilled Standard Binding Buffer and homogenized by several passages through a 26 gauge needle,
then 50 μl were dispensed into each well. The 250-μl
reactions were incubated at room temperature for 1.5
hours, and then harvested by rapid filtration onto
Whatman GF/B glass fiber filters pre-soaked with 0.3%
polyethyleneimine using a 96-well Brandel harvester.
Four rapid 500-μl washes were performed. Filters were
placed in 6-ml scintillation tubes and allowed to dry
overnight. Bound radioactivity was harvested onto 0.3%
polyethyleneamine-treated, 96-well filter mats using a 96well Filtermate harvester. The filter mats were dried, then
scintillant was melted onto the filters and the radioactivity
retained on the filters counted in a Microbeta scintillation
counter. Raw data (dpm) representing total radioligand
binding (i.e., specific + non-specific binding) were plotted
as a function of the logarithm of the molar concentration
of the competitor (i.e., test or reference compound). Nonlinear regression of the normalized (i.e., percent radioligand
resuspendedbinding compared to that observed in the absence of test or reference compound) raw data was
performed in Prism 4.0 (GraphPad Software) using the
built-in three parameter logistic model describing ligand
competition binding to radioligand-labeled sites: y =
bottom + [(top-bottom)/(1 + 10×-logIC50)] where the
denominator equals the residual radioligand binding measured in the presence of 10 μM reference compound (i.e.,
non-specific binding) and the numerator equals the
total radioligand binding observed in the absence of
competitor. The log IC50 (i.e., the log of the ligand concentration that reduces radioligand binding by 50%) is
thus estimated from the data and used to obtain the Ki
by applying the Cheng-Prusoff approximation: Ki = IC50/
(1 + [ligand]/KD) where [ligand] equals the assay radioligand
concentration and KD equals the affinity constant of the
radioligand for the target receptor.
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GTPγ[35S] functional assays

Functional activity was evaluated using GTPγ[35S] assay
in CHO cell membrane extracts expressing recombinant
human CB1 or CB2 receptors as we previously described
[31,55]. Compounds were solubilized in 100% DMSO at
a concentration of 10 mM within 4 hours of the first
testing session. A pre-dilution for the dose response
curve was performed in 100% DMSO and then diluted
100 fold in assay buffer at a concentration 2 fold higher
than the concentration to be tested. Compounds were
tested for agonist activities in duplicate with CP55,940
(Tocris, Bioscience, Ellisville, MI, USA) as reference
agonist. Membranes were mixed with GDP diluted in
assay buffer to give 30 μM solution (volume:volume)
and incubated for at least 15 min on ice. In parallel,
GTPγ[35S] (GE Healthcare, Catalogue number SJ1308)
were mixed with the beads (PVT-WGA (GE Healthcare,
RPNQ001), diluted in assay buffer at 50 mg ml-1
(0.5 mg 10 μl-1) (volume:volume) just before starting the
reaction. The following reagents were successively added
in the wells of an Optiplate (Perkin Elmer): 50 μl of ligand,
20 μl of the membrane: GDP mix, 10 μl of assay buffer for
agonist testing, and 20 μl of the GTPγ[35S]: beads mix.
The plates were covered with a topseal, agitated on an
orbital shaker for 2 min, and then incubated for 1 hour
at room temperature. Then the plates were centrifuged
for 10 min at 2000 rpm and counted for 1 min/well with a
PerkinElmer TopCount reader. Assay reproducibility was
monitored by the use of reference compound CP 55,940.
For replicate determinations, the maximum variability tolerated in the test was of ± 20% around the average of the
replicates. Efficacies (Emax) for CB1 or CB2 are expressed as
a percentage relative to the efficacy of CP 55,940.

Electrophysiology

Methods and procedures used in the electrophysiological
studies were described in detail by us previously [31].
Whole-cell currents were recorded from tsA-201 cells 2–4
days after transfection. NMP compounds were dissolved
in DMSO at a 10 mM concentration and diluted into
external recording solution with a final DMSO concentration no higher than 0.3%. Concentration-response
studies were analyzed with the Hill equation I/Icontrol =
1/[1 + (IC50/[compound])n], where I is the normalized
current at a given concentration of the compound, IC50 is
the concentration of the compound yielding a current that
is half of the control current, Icontrol, and n is the Hill coefficient. For steady-state inactivation curves, data were fitted
using Boltzmann equation I = 1/(1 + e (V−Vh)/k), where Vh is
the half inactivation potential and k is the slope factor.
Current–voltage (I-V) plots were fitted using the modified Boltzmann equation: I = 1/(1 + e−(V−Va)/k) × G ×
(V - Erev), where Erev is the reversal potential, G is the
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maximum slope conductance, k is a slope factor, and
Va is the half activation potential.
Animals

All experiments were conducted following the protocol
approved by the Institutional Animal Care and Use
Committee and all efforts were made to minimize animal
suffering according to the policies and recommendations
of the International Association for the Study of Pain.
Adult male C57BL/6J (wild-type) or CACNA1H knockout
(CaV3.2 null) mice (20-25 g) were used (total of 265 mice).
Animals were housed at a maximum of five per cage
(30 × 20 × 15 cm) with ad libitum access to food and
water. They were kept in controlled temperature of 23 ± 1°C
on a 12 h light/dark cycle (lights on at 7:00 a.m.). When
drugs were delivered by the intraperitoneal (i.p.) route, a
constant volume of 10 ml/kg body weight was injected.
When drugs were administered by intrathecal (i.t.) delivery,
volumes of 10 μl were injected. Intrathecal (i.t) injections
were given to fully conscious mice using the method previously described [56,57]. Animals were manually restrained,
the dorsal fur of each mouse was shaved, the spinal column
was arched, and a 30-gauge needle attached in a PE20
Polyethylene tube to a 25-μl Hamilton microsyringe
(Hamilton, Birmingham, UK) was inserted into the
subarachnoid space between the L4 and L5 vertebrae.
Correct i.t. positioning of the needle tip was confirmed
by a characteristic tail-flick response of animal. Appropriate
vehicle-treated groups were also assessed simultaneously.
All drugs were dissolved in DMSO and control animals
received PBS + DMSO 5%, which was the maximum
DMSO concentration in solutions delivered to animals.
Mice with a targeted disruption of the CaV3.2 gene
(Homozygous CACNA1H, also called α1-3.2) [58] were
purchased from Jackson Laboratories. Different cohorts of
mice were used for each test and each mouse was used only
once. The observer was blind to the experimental conditions in the experiment examining the action of NMP-181
on formalin, open-field and CFA tests (Figures 3 and 4).
Formalin test

The formalin test allows us to evaluate two different types
of pain: neurogenic pain (phase 1) is caused by direct activation of nociceptive nerve terminals, while inflammatory
pain (phase 2) is mediated by a combination of peripheral
input and spinal cord sensitization [33,45]. For this test,
mice were acclimatized in the laboratory for at least
60 minutes before experiments. Animals received 20 μl
of a formalin solution (1.25%) made up in PBS injected
intraplantarily (i.pl.) in the ventral surface of the right
hindpaw. Following i.pl. injections of formalin, the animals
were immediately placed individually into observation
chambers and the time spent licking or biting the injected
paw was recorded and considered as a nociceptive
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response. We observed animals individually from 0–5
min (neurogenic phase) and 15–30 min (inflammatory
phase) and the time spent licking or biting the injected paw
was recorded with a chronometer.

receptor type 2; CFA: Complete Freund's adjuvant; DPA: Dynamic plantar
aesthesiometer; DRG: Dorsal root ganglion; LVA: Low-voltage activated.

CFA-induced persistent inflammatory pain
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The authors read and approved the final manuscript.

In order to induce persistent inflammatory pain, mice received 20 μl of Complete Freund's Adjuvant (CFA) injected
subcutaneously in the plantar surface of the right hindpaw
(i.pl.) [59]. Control groups received 20 μL of PBS in the
right paw. Animals received NMP-181 either spinally
(1–10 μg i.t.-1) or systemically (0.3-3 mg kg-1, i.p.) 3 days
following the CFA injection. Mechanical hyperalgesia was
then measured using the Dynamic Plantar Aesthesiometer
(DPA, Ugo Basile, Varese, Italy). Animals were placed
individually in small enclosed testing arenas (20 cm ×
18.5 cm × 13 cm, length × width × height) on top of a
wire mesh floor. Mice were allowed to acclimate for a
period of 90 minutes. The DPA device was positioned
beneath the animal, so that the filament was directly
under the plantar surface of the ipsilateral hind paw.
Each paw was tested three times per session.
Open-field test

The ambulatory behavior was assessed in an open-field
test exactly as described previously [60]. The apparatus
consisted of a wooden box measuring 40 × 60 × 50 cm
with a frontal glass wall. The floor of the arena was
divided into 12 equal squares and placed in a sound free
room. Animals were placed in the rear left square and
left to explore it freely for 6 min during which time the
number of squares crossed with all paws (crossing) was
counted. The apparatus was cleaned with a 10% alcohol
solution and dried after each individual mouse session.
Statistical analysis

For electrophysiological analyses, data values are presented
as means ± SEM. Statistical significance was determined
using paired t-tests for the comparison of channel biophysical properties before and after treatment. For behavioral
analyses, each column represents the mean ± SEM and
is representative of 2 independent experimental runs
and evaluated by one-way, two-way or analysis of variance (ANOVA) followed by the appropriated Dunnett's
or Tukey’s test. A value of P < 0.05 was considered to
be significant.
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